0
Catégories
TABAC > sevrage tabagique > méthode de sevrage > méthode individuelle > approche pharmacologique > varénicline
varéniclineVoir aussi |
Documents disponibles dans cette catégorie (81)
Ajouter le résultat dans votre panier Affiner la recherche
Effectiveness of varenicline compared with bupropion and nicotine replacement therapy [NRT] for smoking cessation in two smoking specialized in the primary care setting / Antoni Sicras-Mainar (2010)
Titre : Effectiveness of varenicline compared with bupropion and nicotine replacement therapy [NRT] for smoking cessation in two smoking specialized in the primary care setting Type de document : texte imprimé Auteurs : Antoni Sicras-Mainar, Auteur ; Ruth Navarro-Artieda, Auteur ; Silvia Diaz-Cerezo, Auteur ; Veronica Sanz de Burgoa, Auteur Année de publication : 2010 Importance : 1 p. Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : Poster présenté au meeting du SRNT Europe 2010 à Bath [Royaume-Uni] les 6 et 9 septembre 2010 Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7967 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005508 TA 6.2.3 SIC E Fiche Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal / Paul M. Cinciripini (2013)
Titre : Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal Type de document : texte imprimé Auteurs : Paul M. Cinciripini, Auteur Editeur : American Medical Association (AMA) Année de publication : 2013 Collection : JAMA Psychiatry, ISSN 2168-622X num. 70(5) Importance : p.522-533 Langues : Français (fre) Catégories : [TABAC] sevrage tabagique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : In a community sample, varenicline exerts a robust and favorable effect on smoking cessation relative to placebo and may have a favorable (suppressive) effect on symptoms of depression and other affective measures, with no clear unfavorable effect on neuropsychiatric adverse events. En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128024/ Format de la ressource électronique : Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7994 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Effects of varenicline on smoking cessation in adults with stably treated current or past major depression / Robert M. Anthenelli (2013)
Titre : Effects of varenicline on smoking cessation in adults with stably treated current or past major depression : a randomized trial Type de document : texte imprimé Auteurs : Robert M. Anthenelli, Auteur ; Chad Morris, Auteur ; Tanya S. Ramey, Auteur Editeur : American College of Physicians Année de publication : 2013 Collection : Annals of internal medicine, ISSN 0003-4819 num. vol 159, n.6 Importance : p. 390-400 Présentation : ill., tab. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
[TABAC] tabagisme:effet du tabac:effet psychiatrique:dépressionIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Background: Depression is overrepresented in smokers.
Objective: To evaluate smoking abstinence and changes in mood and anxiety levels in smokers with depression treated with varenicline versus placebo.
Design: Phase 4, multicenter, parallel, 1:1 allocation, double-blind, randomization trial. Randomization, stratified by antidepressant use and depression score at baseline, was blocked in sizes of 4. (ClinicalTrials.gov: NCT01078298)
Setting: 38 centers in 8 countries.
Participants: 525 adult smokers with stably treated current or past major depression and no recent cardiovascular events.
Intervention: Varenicline, 1 mg twice daily, or placebo for 12 weeks, with 40-week nontreatment follow-up.
Measurements: Primary outcome was carbon monoxide–confirmed continuous abstinence rate (CAR) for weeks 9 to 12. Other outcomes included CARs assessed during nontreatment follow-up and ratings of mood, anxiety, and suicidal ideation or behavior.
Results: 68.4% versus 66.5% of the varenicline and placebo groups, respectively, completed the study. Varenicline-treated participants had higher CARs versus placebo at weeks 9 to 12 (35.9% vs. 15.6%; odds ratio [OR], 3.35 [95% CI, 2.16 to 5.21]; P < 0.001), 9 to 24 (25.0% vs. 12.3%; OR, 2.53 [CI, 1.56 to 4.10]; P < 0.001), and 9 to 52 (20.3% vs. 10.4%; OR, 2.36 [CI, 1.40 to 3.98]; P = 0.001). There were no clinically relevant differences between groups in suicidal ideation or behavior and no overall worsening of depression or anxiety in either group. The most frequent adverse event was nausea (varenicline, 27.0%; placebo, 10.4%). Two varenicline-group participants died during the nontreatment phase.
Limitations: Some data were missing, and power to detect differences between groups was low in rare events. Smokers with untreated depression, with co-occurring psychiatric conditions, or receiving mood stabilizers and antipsychotics were not included.
Conclusion: Varenicline increased smoking cessation in smokers with stably treated current or past depression without exacerbating depression or anxiety.En ligne : https://annals.org/aim/fullarticle/1738494/effects-varenicline-smoking-cessation [...] Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7935 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Effects of varenicline on smoking cessation in mild-to moderate COPD / D.P. Tashkin (2010)
Titre : Effects of varenicline on smoking cessation in mild-to moderate COPD : a randomized controlled trial Type de document : texte imprimé Auteurs : D.P. Tashkin, Auteur ; Stephen I Rennard, Auteur ; J. Taylor Hays, Auteur Editeur : American College of Chest Physicians Année de publication : 2010 Collection : Chest, ISSN 0012-3692 Importance : 30 p. Présentation : tab. Langues : Français (fre) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : BACKGROUND:
Smoking is the most important risk factor for COPD and accelerates its progression. Despite the health implications, a large proportion of patients with COPD continue to smoke, so finding effective smoking cessation interventions for this population is paramount. To our knowledge, this is the first randomized clinical trial to compare the efficacy and safety of varenicline tartrate vs placebo in smokers with mild to moderate COPD.
METHODS:
In a 27-center, double-blind, multinational study, 504 patients with mild to moderate COPD (postbronchodilator FEV1/FVC, <70%; FEV1 percent predicted normal value, ≥50%) and without known psychiatric disturbances were randomized to receive varenicline (n=250) or placebo (n=254) for 12 weeks, with a 40-week nontreatment follow-up. The primary end point was carbon monoxide-confirmed continuous abstinence rate (CAR) for weeks 9 to 12. A secondary end point was CAR for weeks 9 to 52.
RESULTS:
CAR for weeks 9 to 12 was significantly higher for patients in the varenicline group (42.3%) than for those in the placebo group (8.8%) (OR, 8.40; 95% CI, 4.99-14.14; P<.0001). CAR in the patients treated with varenicline remained significantly higher than in those treated with placebo through weeks 9 to 52 (18.6% vs 5.6%) (OR, 4.04; 95% CI, 2.13-7.67; P<.0001). Nausea, abnormal dreams, upper-respiratory tract infection, and insomnia were the most commonly reported adverse events (AEs) for patients in the varenicline group. Serious AEs were infrequent in both treatment groups. Two patients in the varenicline group and one patient in the placebo group died during the study. Reports of psychiatric AEs were similar for both treatment groups.
CONCLUSIONS:
Varenicline was more efficacious than placebo for smoking cessation in patients with mild to moderate COPD and demonstrated a safety profile consistent with that observed in previous trials.Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7933 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005474 TA 6.2.3.1.4 TAS E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation / Cheryl Oncken (2006)
Titre : Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation Type de document : texte imprimé Auteurs : Cheryl Oncken, Auteur ; David H. Gonzales, Auteur ; Mitchell Nides, Auteur Editeur : American Medical Association (AMA) Année de publication : 2006 Collection : Archives of internal medicine, ISSN 0003-9926 num. Vol. 166 Importance : p. 1571-1577 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Abstract
BACKGROUND:
The selective nicotinic acetylcholine receptor partial agonist, varenicline tartrate, represents a novel type of therapy for smoking cessation. This study evaluated the efficacy, safety, and tolerability of 4 varenicline dose regimens, 2 with progressive dosing over the first week (eg, titrated) and 2 with a fixed dosing schedule (eg, non-titrated), for promoting smoking cessation.
METHODS:
This multicenter, double-blind, placebo-controlled study randomized healthy smokers (aged 18-65 years) to varenicline tartrate, 0.5 mg twice daily nontitrated (n = 129), 0.5 mg twice daily titrated (n = 130), 1.0 mg twice daily nontitrated (n = 129), 1.0 mg twice daily titrated (n = 130), or placebo (n = 129) for 12 weeks to aid in smoking cessation. A 40-week follow-up period assessed long-term efficacy. The primary efficacy measures were the carbon monoxide-confirmed 4-week continuous quit rates by pooled dosage group for weeks 4 through 7 and 9 through 12 and the continuous abstinence rates for weeks 9 through 52.
RESULTS:
Weeks 9 through 12 continuous quit rates were greater in the 1.0-mg group (49.4%) and the 0.5-mg group (44.0%) vs placebo (11.6%; P<.001 vs both doses). Weeks 9 through 52 abstinence rates were greater in the 1.0-mg group (22.4%; P<.001) and the 0.5-mg group (18.5%; P<.001) vs placebo (3.9%). Varenicline was generally well tolerated, with nausea occurring in 16% to 42% of varenicline-treated subjects. Reports of nausea were lower for the titrated vs nontitrated dosing and infrequently led to medication discontinuation.En ligne : https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/410803 Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7951 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease / Nancy A. Rigotti (2010)
Titre : Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease : a randomized trial Type de document : texte imprimé Auteurs : Nancy A. Rigotti, Auteur ; Andrew L. Pipe, Auteur ; Neal L. Benowitz, Auteur ; Carmen Arteaga, Auteur Editeur : Lippincott Williams & Wilkins Année de publication : 2010 Collection : Circulation, ISSN 0009-7322 num. 121:2 Importance : p. 221-229 Langues : Anglais (eng) Catégories : [TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
[TABAC] tabagisme:pathologie:pathologie cardio-vasculaireIndex. décimale : TA 6.2.3.2 Autres produits Résumé : BACKGROUND:
Smoking cessation is a key component of secondary cardiovascular disease prevention. Varenicline, a partial alpha4beta2 nicotinic acetylcholine receptor agonist, is effective for smoking cessation in healthy smokers, but its efficacy and safety in smokers with cardiovascular disease are unknown.
METHODS AND RESULTS:
A multicenter, randomized, double-blind, placebo-controlled trial compared the efficacy and safety of varenicline with placebo for smoking cessation in 714 smokers with stable cardiovascular disease. Participants received varenicline (1 mg twice daily) or placebo, along with smoking-cessation counseling, for 12 weeks. Follow-up lasted 52 weeks. The primary end point was carbon monoxide-confirmed continuous abstinence rate for weeks 9 through 12 (last 4 weeks of treatment). The continuous abstinence rate was higher for varenicline than placebo during weeks 9 through 12 (47.0% versus 13.9%; odds ratio, 6.11; 95% confidence interval [CI], 4.18 to 8.93) and weeks 9 through 52 (19.2% versus 7.2%; odds ratio, 3.14; 95% CI, 1.93 to 5.11). The varenicline and placebo groups did not differ significantly in cardiovascular mortality (0.3% versus 0.6%; difference, -0.3%; 95% CI, -1.3 to 0.7), all-cause mortality (0.6% versus 1.4%; difference, -0.8%; 95% CI, -2.3 to 0.6), cardiovascular events (7.1% versus 5.7%; difference, 1.4%; 95% CI, -2.3 to 5.0), or serious adverse events (6.5% and 6.0%; difference, 0.5%; 95% CI, -3.1 to 4.1). As a result of adverse events, 9.6% of varenicline and 4.3% of placebo participants discontinued study drug.
CONCLUSIONS:
Varenicline is effective for smoking cessation in smokers with cardiovascular disease. It was well tolerated and did not increase cardiovascular events or mortality; however, trial size and duration limit definitive conclusions about safety.En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096941/ Format de la ressource électronique : PDF, HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8369 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Efficacy of varenicline, an alpha-4-beta-2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation / Douglas E. Jorenby (01/06/2006)
Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 001432 TA 6.2.3.1.4 JOR E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Enfin, pouvoir aider à arrêter de fumer / Pfizer (2006)
Titre : Enfin, pouvoir aider à arrêter de fumer Type de document : texte imprimé Auteurs : Pfizer, Auteur Editeur : Pfizer Année de publication : 2006 Importance : [6 p.] Langues : Français (fre) Catégories : [TABAC] sevrage tabagique
[TABAC] sevrage tabagique:méthode de sevrage
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : Brochure expliquant le Champix (tartrate de varénicline) Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=1555 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 002064 TA 6.2.3 PFI C Dépliant/Brochure Bibliothèque FARES Tabac Disponible Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Evénement en rapport avec le suicide / Pfizer (2008)
Titre : Evénement en rapport avec le suicide : idées suicidaires,actes suicidaires et suicides Type de document : texte imprimé Auteurs : Pfizer, Auteur Editeur : Pfizer Année de publication : 2008 Importance : p. 7-12 Présentation : tab. Langues : Français (fre) Catégories : [DIVERS] discipline médicale, paramédicale et scientifique:médecine:médecine spécialisée:psychiatrie
[DIVERS] type de document:rapport
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
[TABAC] tabagisme:effet du tabac:effet psychiatrique:suicideIndex. décimale : TA 6.2.3.2 Autres produits Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8372 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 006003 6.2.3.2 PFI E Rapport Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Final appraisal determination : Varenicline for smoking cessation Type de document : texte imprimé Auteurs : National Institute for Health and Care Excellence (NICE), Auteur Année de publication : 2007 Importance : 14 p. Langues : Anglais (eng) Catégories : [DIVERS] type de document:guide
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.2 Autres produits En ligne : https://www.nice.org.uk/guidance/ta123/documents/varenicline-for-smoking-cessati [...] Format de la ressource électronique : Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8370 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Information for healthcare professionals / Food and Drug Administration (FDA) (Etats-Unis) (2009)
Titre : Information for healthcare professionals : varenicline - marketed as Chantix - and Bupropion (marketed as Zyban, Wellbutrin and generics) Type de document : texte imprimé Auteurs : Food and Drug Administration (FDA) (Etats-Unis), Auteur Année de publication : 2009 Importance : 8 p. Langues : Anglais (eng) Catégories : [DIVERS] discipline médicale, paramédicale et scientifique:médecine:médecine spécialisée:psychiatrie
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
[TABAC] tabagisme:effet du tabac:effet psychiatrique:suicideIndex. décimale : TA 6.2.3.2 Autres produits Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8436 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005033 TA 6.2.3.2 FOO I Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? / Peter Hajek (2013)
Titre : Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? : a randomised controlled trial Type de document : texte imprimé Auteurs : Peter Hajek, Auteur ; Katie Myers Smith, Auteur ; Al-Rehan Dhanji, Auteur ; Hayden McRobbie, Auteur Editeur : BioMed Central Année de publication : 2013 Collection : BMC Medicine, ISSN 1741-7015 Importance : p. 7 Langues : Français (fre) Catégories : [TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:patch à la nicotine
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : Background
Nicotine replacement therapy (NRT) and varenicline are both effective in helping smokers quit. There is growing interest in combining the two treatments to improve treatment outcomes, but no experimental data exist on whether this is efficacious. This double-blind randomised controlled trial was designed to evaluate whether adding nicotine patches to varenicline improves withdrawal relief and short-term abstinence rates.
Methods
117 participants seeking help to stop smoking were randomly allocated to varenicline plus placebo patch or varenicline plus nicotine patch (15 mg/16 hour). Varenicline use commenced one week prior to the target quit date (TQD), patch use started on the TQD. Ratings of urges to smoke and cigarette withdrawal symptoms were collected weekly over 4 weeks post-TQD. Medication use and smoking status were established at 1, 4 and 12 weeks. Participants lost to follow-up were included as continuing smokers.
Results
92% of participants used both medications during the first week after the TQD. The combination treatment generated no increase in nausea or other adverse effects. It had no overall effect on urges to smoke or on other withdrawal symptoms. The combination treatment did not improve biochemically validated abstinence rates at 1 week and 4 weeks post-TQD (69% vs 59%, p=0.28 and 60% vs 59%, p=0.91, in the nicotine patch and placebo patch arm, respectively), or self reported abstinence rates at 12 weeks (36% vs. 29%, p=0.39, NS).
Conclusions
The efficacy of varenicline was not enhanced by the addition of nicotine patches, although further trials would be useful to exclude the possibility of type II error.En ligne : https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-140 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7445 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Life RewardsTM / Pfizer (2006)
Titre : Life RewardsTM : une approche sur mesure du sevrage tabagique Type de document : texte imprimé Auteurs : Pfizer, Auteur Editeur : Pfizer Année de publication : 2006 Importance : [8 p.] Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique
[TABAC] sevrage tabagique:méthode de sevrage
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : Brochure expliquant le programme LifeRewards de Pfizer (Champix) Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=1603 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 002063 TA 6.2.3 PFI L Dépliant/Brochure Bibliothèque FARES Tabac Disponible Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Managing smoking cessation Type de document : texte imprimé Auteurs : Paul Aveyard, Auteur ; Robert West, Auteur Editeur : BMJ Publishing Group Année de publication : 2007 Collection : British Medical Journal num. 335 Importance : p. 37-41 Présentation : ill. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] prévention:témoignage
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : Summary points
Stopping smoking before the age of 40 is crucial to improve health—beyond 40, people lose three months of life expectancy for every further year smoking
The most important factor leading to failure of attempts to stop is nicotine dependence
Nicotine dependence is most effectively treated with a combination of drugs and specialist behavioural support, such as provided by the NHS Stop Smoking Service
Varenicline, bupropion, nortriptyline, and nicotine replacement are all effective
Relapse during or after treatment is common, and treatment is usually needed several times …En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1910650/ Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7960 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro / R. Scott Obach (2006)
Titre : Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro Type de document : texte imprimé Auteurs : R. Scott Obach, Auteur ; Anne E. Reed-Hagen, Auteur ; Suzanne S. Krueger, Auteur ; Beth J. Obach, Auteur Editeur : American Society for Pharmacology and Experimental Therapeutic Année de publication : 2006 Collection : Drug Metabolism and Disposition, ISSN 0090-9556 num. 34:1 Importance : p. 121-130 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.2 Autres produits Résumé : he metabolism and disposition of varenicline (7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine), a partial agonist of the nicotinic acetylcholine receptor for the treatment of tobacco addiction, was examined in rats, mice, monkeys, and humans after oral administration of [14C]varenicline. In the circulation of all species, the majority of drug-related material was composed of unchanged varenicline. In all four species, drug-related material was primarily excreted in the urine. A large percentage was excreted as unchanged parent drug (90, 84, 75, and 81% of the dose in mouse, rat, monkey, and human, respectively). Metabolites observed in excreta arose via N-carbamoyl glucuronidation and oxidation. These metabolites were also observed in the circulation, in addition to metabolites that arose via N-formylation and formation of a novel hexose conjugate. Experiments were conducted using in vitro systems to gain an understanding of the enzymes involved in the formation of the N-carbamoylglucuronide metabolite in humans. N-Carbamoyl glucuronidation was catalyzed by UGT2B7 in human liver microsomes when incubations were conducted under a CO2 atmosphere. The straightforward dispositional profile of varenicline should simplify its use in the clinic as an aid in smoking cessation. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8368 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005999 TA 6.2.3.2 OBA M Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !